ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of$ 0.44. This compares to loss of $0.58 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 13.64%. A quarter ago, it was expected that this company would post a loss of$ 0.56 per share when it actually produced a loss of $0.56, delivering no surprise. Over the last four quarters, the company has surpassed c ...